内分泌临床中的精氨酸加压素缺乏与催产素缺乏
本文综述下丘脑-神经垂体系统中精氨酸加压素(AVP)与催产素(OXT)的生理与临床。AVP缺乏(原中枢性尿崩症)以低渗性多尿、烦渴为特征,可用和肽素检测高精度诊断,去氨加压素治疗需防脱水与低钠血症。OXT缺乏为新近认识,诊断困难,鼻内OXT初步改善社会情绪结局但需随机对照试验验证。
要点
- AVP缺乏表现为低渗性多尿与烦渴,和肽素检测诊断准确性高。
- 去氨加压素治疗AVP缺乏需教育患者预防脱水与低钠血症。
- OXT缺乏与下丘脑-垂体损伤及AVP缺乏相关,可致社会功能障碍。
核心结论
- AVP缺乏诊断依赖和肽素检测区分AVP抵抗与原发性多饮,治疗用去氨加压素并防低钠血症。
- OXT缺乏为新认识临床实体,与下丘脑-垂体损伤及AVP缺乏相关,诊断与治疗证据尚有限。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- AVP经V2受体介导集合管水通道蛋白2插入调节水平衡,经V1受体调节血管张力。
- OXT参与分娩与泌乳,也影响代谢、社会行为、情绪加工与应激调节。
- AVP缺乏由手术、创伤、肿瘤、浸润性或自身免疫病、血管事件或遗传因素所致。
- OXT缺乏与社交功能障碍、焦虑及生活质量下降相关。
- MDMA激发试验与神经physin I作为替代标志物正在研究中。
关键数值与推荐
- AVP缺乏特征为低渗性多尿、烦渴与脱水风险,需与AVP抵抗及原发性多饮鉴别。
- 和肽素基础检测提供高诊断准确性。
- OXT基础水平不可靠且激发试验有限,诊断具挑战性。
- 鼻内OXT初步研究显示可改善社会情绪结局,但需随机对照试验。
临床怎么用
- 怀疑AVP缺乏时用和肽素检测鉴别AVP抵抗与原发性多饮。
- 去氨加压素治疗AVP缺乏需患者教育以平衡脱水与低钠血症风险。
- 下丘脑-垂体损伤伴AVP缺乏患者应评估社会功能障碍与焦虑等OXT缺乏表现。
- OXT缺乏诊断与治疗尚未常规化,MDMA激发与神经physin I待验证。
局限性
- OXT缺乏诊断方法有限,基础OXT水平不可靠。
- 鼻内OXT证据仅来自初步研究,缺乏随机对照试验。
- MDMA激发试验与神经physin I为在研手段,尚未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The hypothalamo-neurohypophysial system consists of specialized neurons in the supraoptic and paraventricular nuclei that project to the central nervous system and the posterior pituitary, where they secrete arginine vasopressin (AVP) and oxytocin (OXT) into the systemic circulation. AVP is the key endocrine regulator of water balance via V2 receptor-mediated aquaporin-2 insertion in renal collecting ducts and modulates vascular tone via V1 receptors. OXT plays a central role in labor and lactation, but also influences metabolism, social behavior, emotional processing, and stress regulation. AVP deficiency (formerly central diabetes insipidus) results from hypothalamic-posterior pituitary disruptions or injury due to surgery, trauma, tumors, infiltrative or autoimmune disease, vascular events, or genetic causes. It is characterized by hypotonic polyuria, polydipsia, and dehydration risk, and is diagnosed by distinguishing it from AVP resistance and primary polydipsia, with copeptin-based tests providing high diagnostic accuracy. Treatment relies on desmopressin and careful education to prevent both dehydration and hyponatremia. In contrast, OXT deficiency has only recently been recognized as a potential clinical entity, particularly in patients with hypothalamic-pituitary disruptions or injury and concurrent AVP deficiency. Emerging evidence links it to social dysfunction, anxiety, and reduced quality of life. Diagnosis remains challenging due to unreliable basal OXT levels and limited stimulation tests; novel approaches, including 3,4-methylenedioxymethamphetamine (MDMA) challenge and neurophysin I as a surrogate marker, are under investigation. Preliminary studies suggest intranasal OXT may improve socioemotional outcomes, but robust evidence from randomized controlled trials is needed.
引用
- Atila C, Refardt J, Christ-Crain M, et al. Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic. J Clin Endocrinol Metab. 2026. PMID: 41363127. doi:10.1210/clinem/dgaf651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。